Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05919108
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:21.022424+00:00
Published At
2025-09-09T00:00:00+00:00
Record Updated At
2025-09-09
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Anatomic Stage I Breast Cancer", "Anatomic Stage II Breast Cancer", "Anatomic Stage III Breast Cancer", "Invasive Breast Lobular Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-09-09"
protocolSection.identificationModule.nctId
"NCT05919108"
protocolSection.identificationModule.officialTitle
"Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Anatomic Stage I Breast Cancer (protocolSection.conditionsModule.conditions)
  • Anatomic Stage II Breast Cancer (protocolSection.conditionsModule.conditions)
  • Anatomic Stage III Breast Cancer (protocolSection.conditionsModule.conditions)
  • Invasive Breast Lobular Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.